Everything below concerns IGF-1 marker. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
== Chairman of the Transitional Sovereignty Council (2021–present) == On 25 October 2021, al-Burhan led the October 2021 Sudanese coup d'état to overthrow the civilian government of Prime Minister Abdalla Hamdok. On 21 November 2021, all political prisoners were freed and Abdalla Hamdok was reinstated as prime minister as part of an agreement with the civilian political parties. Hamdok was also allowed to return leading the transitional government. After the coup, Burhan integrated Islamists into sources of power, in particular the SAF. Muslim Brotherhood members who had been active under the Bashir regime became among the principal supporters of al-Burhan and his rule. On 4 December 2021, al-Burhan told Reuters in an interview that the Sudanese military will "exit politics" following the elections scheduled for July 2023, stating, "When a government is elected, I don't think the army, the armed forces, or any of the security forces will participate in politics. This is what we agreed on and this is the natural situation." On 9 December 2021, al-Burhan warned of possible measures against foreign diplomatic missions for their alleged incitement against the Sudanese army. He also reiterated his commitment to the political agreement struck with Prime Minister Hamdok in November 2021. On 20 December 2021, al-Burhan voiced his support for Hamdok, adding that recent appointments had been made as the result of coordination between him and the prime minister and in line with the 21 November 2021 political agreement.
Like CMX-1152, the herbal mixture known as Protandim that supplanted it was marketed by Lifeline as an "anti-aging" supplement that increases the body's antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as GNC; however, in 2009, after several consecutive years of multimillion-dollar losses, the company, which by then was doing business under the name LifeVantage, stopped marketing it through retailers and switched to multi-level marketing, selling it instead through a network of commissioned independent distributors. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of Metabolife) as the company's CEO and president. Beginning in 2005, Protandim was produced under a manufacturing agreement with The Chemins Company of Colorado Springs, Colorado. In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research & Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (TrueScience). In 2006, biochemist Joe M. McCord joined the LifeVantage board of directors as the company's director of science. McCord, who is listed by the U.S. Securities and Exchange Commission as a LifeVantage insider shareholder, served as a spokesperson for Protandim and was responsible for distributor training and product research.
=== Pharmacokinetics === The pharmacokinetics of spironolactone have not been studied well, which is in part because it is an old medication that was developed in the 1950s. Nonetheless, much has been elucidated about the pharmacokinetics of spironolactone over the decades.
Kyiv came under air attack in the early hours of the morning. Vitali Klitschko, Kyiv's Mayor, said that debris from intercepted missiles struck the city zoo in the Solomianskyi District and the Shevchenkivskyi District, as well as several cars, and wounded three people. According to Kyiv's military administrator, Serhiy Popko, the attack was "exceptional", as it involved "the maximum number of attack missiles in the shortest period of time." Ukraine stated all eighteen missiles were shot down, including six Kh-47M2 Kinzhal missiles. The attacks came from the north, south and east while being launched from air, land and sea, according to Ukrainian military commander Valerii Zaluzhny. However, Russian Defence Minister Sergei Shoigu dismissed the Ukrainian claims, saying that they had launched a lesser amount of missiles. The Russian Ministry of Defence claimed to have destroyed a US-built Patriot surface-to-air missile defense system with a Kinzhal missile. A US official later told CNN that a Patriot system was likely damaged but not destroyed during the attack, and that assessments for potential damage were ongoing. According to a US official the Patriot system could be repaired in Ukraine. Due to modular nature of the system it may just require the replacement of a damaged component with a new one. Denis Pushilin, head of the Russian-backed Donetsk People's Republic, said that Russian forces had seized several Ukrainian positions near Avdiivka.
Sources: en.wikipedia.org
In arguing that West Germany was not "Americanized" after the war, Logemann joins a long debate about American consumer capitalism's power, sweep, and depth of influence in the developed world through the second half of the twentieth century. In pointed contrast to Reinhold Wagnleitner's Coca-colonization and the Cold War (1994) and Victoria de Grazia's Irresistible Empire (2005), Logemann argues that, for all the noisy commentary, pro and con, about postwar Americanization, West Germans shaped their version of the affluent society according to deeply held and distinctly un-American values. Rather than a sweeping homogenization of the developed world, postwar affluence ran along "different paths to consumer modernity" ... Instead of the "consumer-as-citizen" (whom Lizabeth Cohen, in The Consumer's Republic [2003], defined as the main social type in postwar America), West Germans promoted the social consumer who practiced "public consumption," which Logemann defines as "the provision of publicly funded alternatives to private consumer goods and services in areas ranging from housing to transportation or entertainment" (p. 5). The Freakonomics Radio podcast episode "How the Supermarket Helped America Win the Cold War (Ep. 386)" explores the impact that the supermarket had and has on American culture, including the depth of policy decisions by the US Government that impacted agriculture, as well as serving a propaganda weapon against the Soviet Union.
The presidential transition period began following Trump's victory in the 2024 U.S. presidential election, though Trump had chosen Linda McMahon and Howard Lutnick to begin planning for the transition in August 2024. According to The New York Times, Trump was "superstitious" and preferred to avoid discussing the presidential transition process until after Election Day. His transition team relied on the work of the America First Policy Institute, rather than the Heritage Foundation, a conservative think tank that garnered controversy during the election for Project 2025, a set of initiatives that would reshape the federal government. By October, he had not participated in the federal presidential transition process, and he had not signed a required ethics pledge, as of November. During the transition period, Trump announced nominations for his cabinet and administration. Trump was inaugurated on January 20, 2025. He was sworn in by Chief Justice John Roberts. The inauguration occurred indoors in the Capitol Rotunda as a result of a severe cold wave.
=== 2000: Glaxo Wellcome and SmithKline Beecham merger === Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed on 27 December that year, forming GlaxoSmithKline (GSK). The company's global headquarters were at GSK House, Brentford, London, officially opened in 2002, by then-Prime Minister Tony Blair. The building was erected at a cost of £300 million and as of 2002 was home to 3,000 administrative staff.
=== Comparison between conventional and in situ analysis === Conventional analysis Conventionally, monazite is separated from samples by dissolution and chemical methods. Single or fractions of crystals are selected for dating, usually by thermal ionization mass spectrometry (TIMS). That means one age is generated for a single monazite crystal or for a group of crystals. The age information obtained is obviously inconsistent and inaccurate, because even a single monazite crystal contains zones of different ages. Also, mechanical separation for monazite often destroys the associated textural and spatial information in the monazite crystals, which is crucial in interpreting relationships between domains and geological environments. In-situ analysis
Omeprazole was first made in 1979 by Swedish AB Hässle, part of Astra AB. It was the first of the proton pump inhibitors (PPI). Astra AB, now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the US Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide). The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant. Prilosec is owned by Procter & Gamble in alliance with AstraZeneca and the product is designed to address frequent heartburn, which can be triggered by various factors such as certain foods, stress, and smoking. Prilosec was first introduced in 1989 as a prescription medication approved by the FDA for the treatment of severe heartburn. In 2003, Prilosec OTC was launched as the first over-the-counter option for managing frequent heartburn. It is known for its advertising campaign featuring Larry the Cable Guy as the spokesperson for the brand, during the 2010s, emphasizing the concept of "Zero Heartburn".
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.